The potential use of rabies virus glycoproteinderived peptides to facilitate drug delivery into the central nervous system: a mini review

Rachel Huey, Susan Hawthorne

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rabies virus glycoprotein (RVG), a 505 amino acid type-1 glycoprotein, is responsible for the neurotrophic nature of the rabies virus infection. Despite varying reports in the literature as to which receptor is ultimately responsible for interaction of RVG with the nervous system, there is a strong argument for major nicotinic acetylcholine receptor (nAChR) involvement. Peptide derivatives of RVG, such as rabies virus-derived peptide (RDP) and RVG-29 are emerging as promising targeting ligands for the delivery of therapeutics to the central nervous system (CNS). The neurotrophic nature of RVG and indeed its derivatives may be due to interaction with ubiquitous nAChRs principally, but also association with other neural cell-specific molecules such as neural cell adhesion molecule (NCAM). It is possible that nAChR-mediated uptake of RVG-derived peptides may serve as an attractive new approach for targeting drug delivery to the brain. Potential application of this type of drug delivery system extends to many diseases affecting the CNS, where specific and effective drug delivery is normally a challenging process
LanguageEnglish
Pages1-7
JournalJournal of Drug Targeting
Early online date10 Aug 2016
DOIs
Publication statusE-pub ahead of print - 10 Aug 2016

Fingerprint

Rabies virus
Central Nervous System
Glycoproteins
Peptides
Pharmaceutical Preparations
Nicotinic Receptors
Drug Delivery Systems
Neural Cell Adhesion Molecules
Central Nervous System Diseases
Virus Diseases
Nervous System
Ligands
Amino Acids
Brain
rabies virus glycoprotein peptide

Keywords

  • rabies virus
  • nicotinic acetylcholine receptor
  • peptide
  • targeted
  • delivery
  • cental nervous system

Cite this

@article{9f4a8012285c41e3add79474838efb3a,
title = "The potential use of rabies virus glycoproteinderived peptides to facilitate drug delivery into the central nervous system: a mini review",
abstract = "Rabies virus glycoprotein (RVG), a 505 amino acid type-1 glycoprotein, is responsible for the neurotrophic nature of the rabies virus infection. Despite varying reports in the literature as to which receptor is ultimately responsible for interaction of RVG with the nervous system, there is a strong argument for major nicotinic acetylcholine receptor (nAChR) involvement. Peptide derivatives of RVG, such as rabies virus-derived peptide (RDP) and RVG-29 are emerging as promising targeting ligands for the delivery of therapeutics to the central nervous system (CNS). The neurotrophic nature of RVG and indeed its derivatives may be due to interaction with ubiquitous nAChRs principally, but also association with other neural cell-specific molecules such as neural cell adhesion molecule (NCAM). It is possible that nAChR-mediated uptake of RVG-derived peptides may serve as an attractive new approach for targeting drug delivery to the brain. Potential application of this type of drug delivery system extends to many diseases affecting the CNS, where specific and effective drug delivery is normally a challenging process",
keywords = "rabies virus, nicotinic acetylcholine receptor, peptide, targeted, delivery, cental nervous system",
author = "Rachel Huey and Susan Hawthorne",
year = "2016",
month = "8",
day = "10",
doi = "10.1080/1061186X.2016.1223676",
language = "English",
pages = "1--7",

}

TY - JOUR

T1 - The potential use of rabies virus glycoproteinderived peptides to facilitate drug delivery into the central nervous system: a mini review

AU - Huey, Rachel

AU - Hawthorne, Susan

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Rabies virus glycoprotein (RVG), a 505 amino acid type-1 glycoprotein, is responsible for the neurotrophic nature of the rabies virus infection. Despite varying reports in the literature as to which receptor is ultimately responsible for interaction of RVG with the nervous system, there is a strong argument for major nicotinic acetylcholine receptor (nAChR) involvement. Peptide derivatives of RVG, such as rabies virus-derived peptide (RDP) and RVG-29 are emerging as promising targeting ligands for the delivery of therapeutics to the central nervous system (CNS). The neurotrophic nature of RVG and indeed its derivatives may be due to interaction with ubiquitous nAChRs principally, but also association with other neural cell-specific molecules such as neural cell adhesion molecule (NCAM). It is possible that nAChR-mediated uptake of RVG-derived peptides may serve as an attractive new approach for targeting drug delivery to the brain. Potential application of this type of drug delivery system extends to many diseases affecting the CNS, where specific and effective drug delivery is normally a challenging process

AB - Rabies virus glycoprotein (RVG), a 505 amino acid type-1 glycoprotein, is responsible for the neurotrophic nature of the rabies virus infection. Despite varying reports in the literature as to which receptor is ultimately responsible for interaction of RVG with the nervous system, there is a strong argument for major nicotinic acetylcholine receptor (nAChR) involvement. Peptide derivatives of RVG, such as rabies virus-derived peptide (RDP) and RVG-29 are emerging as promising targeting ligands for the delivery of therapeutics to the central nervous system (CNS). The neurotrophic nature of RVG and indeed its derivatives may be due to interaction with ubiquitous nAChRs principally, but also association with other neural cell-specific molecules such as neural cell adhesion molecule (NCAM). It is possible that nAChR-mediated uptake of RVG-derived peptides may serve as an attractive new approach for targeting drug delivery to the brain. Potential application of this type of drug delivery system extends to many diseases affecting the CNS, where specific and effective drug delivery is normally a challenging process

KW - rabies virus

KW - nicotinic acetylcholine receptor

KW - peptide

KW - targeted

KW - delivery

KW - cental nervous system

U2 - 10.1080/1061186X.2016.1223676

DO - 10.1080/1061186X.2016.1223676

M3 - Article

SP - 1

EP - 7

ER -